Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager . Agreement also gives Novartis ...

AbCellera (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the ...

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live WOBURN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) ...

CaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 ...

(“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its ...

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation ...

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of ...

Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company ...

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with ...

Pre-conference AI in pharmacometrics workshop and four scientific poster presentations highlight PumasAI’s presence at the ...